Skip to main content
Back
TGRNF logo

Tong Ren Tang Technologies Co. Ltd.

Data quality: 100%
Oversold
TGRNF
OTC Healthcare Drug Manufacturers - General
$0.55
$0.00 (0.00%)
Mkt Cap: 704.42M
Day Range
$0.55 $0.55
52-Week Range
$0.55 $0.70
Volume
1,000
50D / 200D Avg
$0.69 / $0.67
Prev Close
$0.55

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (627 peers)

Metric Stock Sector Median
P/E 1.4 0.4
P/B 0.1 2.9
ROE % 7.4 3.7
Net Margin % 7.2 3.9
Rev Growth 5Y % 12.0 10.0
D/E 0.3 0.2

Analyst Price Target

No analyst coverage available

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 $0.51
$0.51 – $0.51
 8.7 B 1
FY2026 $0.46
$0.46 – $0.46
 8 B 1

Key Takeaways

Revenue grew 12.04% annually over 5 years — strong growth
Earnings declined -11.59% over the past year
Debt/Equity of 0.34 — conservative balance sheet
Negative free cash flow of -158.56M
P/E of 1.35 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 4.86%

Growth

Revenue Growth (5Y)
12.04%
Revenue (1Y)7.18%
Earnings (1Y)-11.59%
FCF Growth (3Y)N/A

Quality

Return on Equity
7.40%
ROIC7.67%
Net Margin7.19%
Op. Margin13.57%

Safety

Debt / Equity
0.34
Current Ratio3.81
Interest Coverage15.28

Valuation

P/E Ratio
1.35
P/B Ratio0.10
EV/EBITDA-1.01
Dividend Yield0.04%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 7.18% Revenue Growth (3Y) 10.07%
Earnings Growth (1Y) -11.59% Earnings Growth (3Y) -5.39%
Revenue Growth (5Y) 12.04% Earnings Growth (5Y) 2.78%
Profitability
Revenue (TTM) 7.26B Net Income (TTM) 521.80M
ROE 7.40% ROA 3.62%
Gross Margin 39.64% Operating Margin 13.57%
Net Margin 7.19% Free Cash Flow (TTM) -158.56M
ROIC 7.67% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.34 Current Ratio 3.81
Interest Coverage 15.28 Dividend Yield 0.04%
Valuation
P/E Ratio 1.35 P/B Ratio 0.10
P/S Ratio 0.10 PEG Ratio -1.13
EV/EBITDA -1.01 Dividend Yield 0.04%
Market Cap 704.42M Enterprise Value -999.86M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 7.26B 6.77B 5.99B 5.40B 4.61B
Net Income 521.80M 590.19M 582.89M 507.25M 467.55M
EPS (Diluted) 0.41 0.46 0.46 0.40 0.37
Gross Profit 2.88B 2.85B 2.59B 2.29B 2.07B
Operating Income 985.16M 1.12B 1.21B 1.08B 943.55M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 14.41B 13.51B 12.48B 11.59B 10.94B
Total Liabilities 4.24B 3.86B 3.47B 3.44B 3.19B
Shareholders' Equity 7.21B 6.89B 6.48B 5.98B 5.73B
Total Debt 2.43B 1.63B 1.59B 1.64B 1.69B
Cash & Equivalents 4.13B 2.75B 3.72B 3.25B 2.95B
Current Assets 10.83B 10.06B 9.07B 8.13B 7.45B
Current Liabilities 2.84B 2.24B 2.05B 2.46B 2.45B

Strategy Scores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Growth Price/Sales Ratio Focus (Ken Fisher)
#544 of 618
12
Value Defensive Investing (Benjamin Graham)
#234 of 710
37

Recent Activity

Entered Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entered Defensive Investing (Benjamin Graham)
Mar 24, 2026